This study was conducted to identify enzyme systems eventually catalysing a local cerebral metabolism of citalopram, a widely used antidepressant of the selective serotonin reuptake inhibitor type. The metabolism of citalopram, of its enantiomers and demethylated metabolites was investigated in rat brain microsomes and in rat and human brain mitochondria. No cytochrome P-450 mediated transformation was observed in rat brain. By analysing H 2 O 2 formation, monoamine oxidase A activity in rat brain mitochondria could be measured. In rat whole brain and in human frontal cortex, putamen, cerebellum and white matter of five brains monoamine oxidase activity was determined by the stereoselective measurement of the production of citalopram propionate. All substrates were metabolised by both forms of MAO, except in rat brain, where monoamine oxidase B activity could not be detected. Apparent K m and V max of S-citalopram biotransformation in human frontal cortex by monoamine oxidase B were found to be 266 M and 6.0 pmol min −1 mg −1 protein and by monoamine oxidase A 856 M and 6.4 pmol min −1 mg −1 protein, respectively. These K m values are in the same range as those for serotonin and dopamine metabolism by monoamine oxidases. Thus, the biotransformation of citalopram in the rat and human brain occurs mainly through monoamine oxidases and not, as in the liver, through cytochrome P-450.
Introduction
Over the last 20 years there has been a growing interest in the role of cytochrome P-450 (P450) as well as in the genetic factors determining the biotransformation and subsequent pharmacodynamic actions of psychotropic drugs. Consequently, patients receiving therapeutic doses of psychotropic drugs regularly have their plasma levels monitored on the assumption that plasma concentrations reflect brain levels of the medicaments. However, this assumption may be questioned since there is some evidence that psychotropic drugs (and other xenobiotics) are not only metabolised in liver, intestine and other peripheral organs, but also in the central nervous system. However, studies on drug metabolism in the brain generally focus upon the role of P450, and rarely upon that of monoamine oxidases (MAO). [1] [2] [3] In fact, some compounds may be locally metabolised by MAO to active and toxic metabolites, as demonstrated for MPTP (1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine), which is firstly oxidised to MPDP + and then to MPP + . This compound affects dopaminergic neurons and leads to Parkinsonism. 4 The recently introduced selective serotonin reuptake inhibiting (SSRIs) antidepressants are effective and generally safe drugs. Some authors [5] [6] [7] [8] recommend their combination with MAO inhibitors in therapy-resistant depression, but the risks of developing a serotonin syndrome in this situation are considered high. [9] [10] [11] Serotonin syndromes have been described after combination of MAO inhibitors with the SSRIs sertraline, 12, 13 fluoxetine, 14, 15 citalopram 16 and with the serotonergic antidepressant clomipramine. 16 The racemic antidepressant citalopram is an SSRI, of which mainly the S-enantiomer is pharmacologically active. 17 In human liver microsomes, several P450 isoforms including CYP2C19, CYP3A4 and CYP2D6, metabolise citalopram to demethylcitalopram, which is then further metabolised to didemethylcitalopram. 18, 19 In a minor pathway, MAO mediates the production of citalopram propionate from citalopram, demethyl-and didemethylcitalopram, as shown in human liver 20 and in human blood. 21 The study by Rochat 20 seems to be the first reporting about the metabolism of an SSRI by MAO. In a detailed study on the metabolism of citalopram, 75% of labeled citalopram, given as a single dose to volunteers, was recovered in the urine within 17 days. Most of this radioactivity (75%) was made up of citalopram, demethyl-and didemethylcitalopram and/or their glucuroconjugated metabolites. Twelve per cent and 7% of the radioactivity was attributable to the glucuronidated form of citalopram propionate and to citalopram N-oxide, respectively. 22 In another study in human volunteers, only citalopram propionate, but not demethylated metabolites, could be found in plasma following a single intravenous dose of citalopram. 23 In general, antidepressants, including those SSRIs examined so far, have only weak, if any, MAO inhibitory activity. [24] [25] [26] Presumably, the syndrome which appears after combining SSRIs with MAO inhibitors stems from a synergistic action on the levels of serotonin in the synaptic cleft. Whether such effects could arise through mutual inhibition of each drug's inactivation remains an open question.
In the present study, we investigated the hypothesis that MAO, in contrast to P450, preferentially metabolises citalopram, demethyl-and didemethylcitalopram in subcellular rat and human brain preparations using in vitro incubation techniques. The metabolism of citalopram in rat brain microsomes by P450 was analysed by measuring the production of demethylcitalopram. MAO activity on citalopram, its enantiomers and N-demethylated metabolites was investigated by measuring their transformation to citalopram propionate in rat and human brain mitochondria and by measuring the appearance of H 2 O 2 in rat brain mitochondria.
Material and methods
The following drugs were gifts: amitriptyline and its N-demethylated metabolite nortriptyline, the enantiomers of citalopram (S-and R-citalopram), the racemates of citalopram, demethyl-and didemethylcitalopram and citalopram propionate (Lundbeck AS, Copenhagen, Denmark), S-flurbiprofen (Boots Ltd, Nottingham, UK) and maprotiline (Novartis, Basel, Switzerland). Other drugs and chemicals were obtained from commercial sources and were of the purest available quality.
All procedures involving human and animal tissues were done in strict accordance with the Helsinki Declaration of 2000 and with the Swiss Governmental directives concerning scientific research. SpragueDawley rats purchased from Madö rin Kleintierfarm, Fü llinsdorf, Switzerland, each weighing 200-250 g were used for these experiments. At the start, the rats were decapitated, the brains removed and transferred into ice cold buffer C (pH 7. 4 sucrose). Blood vessels and pial membranes were removed and the brains immediately processed to subcellular fractions. Human autopsy material was obtained at the Département de Psychiatrie, Hô pitaux Universitaires de Genève, Switzerland. Tissue obtained 5-10 h post mortem consisted of five brains (frontal cortex, cerebellar cortex, putamen, white matter underlying the frontal cortex) from subjects aged 75-98 years. Four of the subjects had suffered from degenerative dementia, three subjects died from cardiac failure and two of pneumonia. They were medicated with various drugs, but no known MAO-A or MAO-B inhibitory drugs, no citalopram and no other SSRIs were prescribed during at least 30 days preceding death. Drugs prescribed during the week before death included: Enalapril, propylthiouracil, zolpidem, lorazepam, diazepam, acenocoumarol, nadroparin, budesonid, nitroglycerin, haloperidol, morphine, paracetamol, mefenamic acid, olanzapin, biperiden, amiodarone, metoclopramid, xylocaine, furosemide, levomepromazine, propafenon and metarnizol. Irreversible MAOinhibitors are not available in Switzerland. No data were available with regard to the smoking status of the patients. After collection, tissue samples were deep frozen in liquid nitrogen and stored at −80°C until preparation of subcellular fractions.
The preparation of subcellular fractions was adapted from a procedure described by Jolivalt 27 and was the same for all tissues except that the human samples had to be thawed in buffer A (0.32 M sucrose, 50 mM KH 2 PO 4 , 1 mM EDTA, 0.1 mM dithiothreitol, pH 7.4) and the main blood vessels had to be removed before further processing. Centrifugation was carried out at 4°C and the biological samples were kept on ice during the manipulations. Several rat brains were pooled for the preparation of rat subcellular fractions.
Manual homogenization of the samples using a glass grinder was done in three volumes of ice-cold buffer A. The homogenate was centrifuged for 3 min at 1900 g. The pellet was washed once with buffer A and again centrifuged as above. The supernatant was then centrifuged for 20 min at 12 000 g. The pellet obtained was washed once with buffer A and centrifuged for 20 min at 12 000 g and then re-suspended in buffer C (mitochondrial fraction). The supernatant from the first 12 000 g centrifugation was centrifuged at 105 000 g for 75 min, washed once with buffer B (100 mM KH 2 PO 4 , 0.2 mM EDTA, 0.5 mM dithiothreitol, 20% (v/v) glycerol, pH 7.4) and again centrifuged for 75 min at 105 000 g. The final pellet was resuspended in buffer B (microsomal fraction). Protein concentration was determined using an automated procedure 28 or by using the Cu 2+ and Folin-Ciocalteu's phenol reagent method. 29 Subcellular preparations were stored at −80°C until use. The determination of P450-activities with citalopram and amitriptyline as substrates was carried out according to methods described earlier. 30, 31 Analyses of demethylcitalopram and nortriptyline were performed using a Hewlett-Packard HP 5890 Series II gas chromatograph linked to a HP 5972 mass spectrometer. Kynuramine deamination by MAO was monitored spectrophotometrically by measuring the appearance of 4-hydroxyquinoline. 32 Incubations of brain mitochondrial preparations were carried out under the following conditions unless otherwise indicated: prior to use, the mitochondrial preparations were thawed at 4°C for 1 h. The incubation mixture without the substrate was preincubated for 15 min at 37°C. Human mitochondrial incubations were carried out in a final volume of 0.3 ml at pH 7.4 containing 1 mg ml −1 mitochondrial proteins, 0.25 mM substrate (S-and R-citalopram, and citalopram, demethyl-and didemethyl citalopram as their racemates) and 0.15 M phosphate buffer for 240 min at 37°C. Rat mitochondrial incubations were carried out for 120 min in a final volume of 0.6 ml, under the same conditions as the human incubations. The incubations were stopped by addition of 0.1 ml of 1 M HCl. Selective inhibition of MAO-A and MAO-B was carried out by preincubating the samples at 37°C for 15 min with 400 nM clorgyline or deprenyl, respectively, before the substrate was added. To block both MAO-A and MAO-B simultaneously, both selective inhibitors were used together at a final concentration of 400 nM each. In all our experiments, when both selective inhibitors were used simultaneously, no production of citalopram propionate or of H 2 O 2 could be measured. To examine the kinetics of S-citalopram biotransformation by MAO-B, the concentration of the substrate was varied between 0.1 mM and 1.2 mM. All incubations were done in triplicate except where indicated otherwise.
Citalopram propionate was extracted from mitochondrial preparations as follows: Using a modification of a procedure previously described, 33 1 ml of 0.6% KH 2 PO 4 (pH = 3), 50 ng of the internal standard (S-flurbiprofen) and 6 ml heptane-isoamyl-alcohol (98.5:1.5) was added to the incubation mixture which was shaken for 20 min and centrifuged at 3000 g for 8 min at 8°C. The organic layer was transferred to another tube and 1.5 ml 0.1 N NaOH were added. The tube was shaken for 20 min and centrifuged at 3000 g for 8 min at 8°C. The organic layer was discarded, 200 l 1 M HCl and 800 l ethylacetate were added. After shaking for 20 min and centrifugation at 2300 g for 8 min at 8°C, the organic layer was recovered and evaporated to dryness at 45°C under a flow of nitrogen in order to avoid contamination with any remaining aqueous solution. Re-suspension took place in 300 l ethylacetate. Derivatisation was performed with 50 l methyliodide in the presence of 10-20 g K 2 CO 3 for 1 h at 64°C. After evaporation to dryness at room temperature under a flow of nitrogen, the dried sample was reconstituted in 170 l of mobile phase of which 100 l were injected. The analysis of R-and S-citalopram propionate was carried out by HPLC on an HP 1100 system. The lower limit of quantification of each enanti- 34 Incubations were performed in the presence of rat brain mitochondria in a pH 8.0 buffer (Na 2 HPO 4 /KH 2 PO 4 , 0.07 M KCl). The protein concentration was set to a final value 0.4 mg ml −1 of rat brain mitochondria. The total volume of incubation was 0.6 ml. The protein suspension was preincubated for 5 min with or without either deprenyl (100 nM) and/or clorgyline (100 nM) to test for MAO-A and/or MAO-B activity, respectively. HRP was preincubated at 37°C and at pH 8 alone for at least 30 min and added to the protein suspension (final concentration of 2 U ml −1 ). Preincubation was carried out for another 25 min. HPPA and the substrate under study (citalopram, R-and S-citalopram or demethyl citalopram) were then added to the reaction mixture to a final concentration of 100 M and 1 mM, respectively. The reaction between hydrogen peroxide, HRP and p-hydroxypropionic acid was monitored spectrofluorimetrically at exc = 323 nm and em = 411 nm on a Safas flx spectrofluorimeter (Monaco, France).
Results
In order to assess P450 activity, citalopram N-demethylation was measured in vitro in incubations containing rat brain microsomes. In the presence of an NADPregenerating system, 17.8 ± 1.85 ng demethylcitalopram were found. In the absence of the NADP-regenerating system and in incubations without microsomes 16.0 ± 1.09 ng and 18.4 ± 2.12 ng demethylcitalopram were measured. These three values (each is the mean of eight incubations ± SD) correspond to the contamination of citalopram by demethylcitalopram which amounts to 0.2%. To ensure that P450 activity was present in these microsomes, amitriptyline demethylase activity was assessed by measuring the production of nortriptyline according to Voirol et al. 30 A clear production of nortriptyline in the presence of the NADPregenerating system and with microsomes of the same batch as those used for the incubations with citalopram could be measured (13.1 ng of produced nortriptyline, mean of two incubations), whereas without microsomes, no nortriptyline could be found.
MAO activities were measured in rat and human autopsy brain mitochondria. In order to ascertain MAO activity in our incubations, we measured the K m and V max values of kynuramine deamination in rat brain and human frontal cortex. The K m (M) and V max (nmol min −1 mg −1 of protein, incubations in triplicates, mean ± SD) values were 86 ± 6.1 and 1.81 ± 0.049 for rat MAO-A, 62 ± 4.7 and 2.1 ± 0.061 for rat MAO-B and 84 ± 4.7 and 0.98 ± 0.061 for human MAO-B. Measured K m values correspond well with literature data available for rat brain (90 M for MAO-A and 60 M for MAO-B). 32 Direct assessment of MAO-catalysed metabolism of Table 2 , this production is essentially due to MAO-A.
Citalopram propionate production was measured in mitochondria prepared from whole rat brain homogenates and from five human brains (frontal cortex, cerebellum, putamen and white matter). Production of citalopram propionate by rat brain mitochondria was linear at least for 120 min and up to a concentration of With rat brain mitochondria, the highest production was found with demethylcitalopram as substrate, 2.4 times higher than with S-citalopram, the substrate with the lowest production ( Table 1) . In rat brain, MAO-A activity predominated (Table 2 ). However only with demethyl-and didemethylcitalopram as substrates, but not with citalopram, could a small amount of citalopram propionate catalysed by MAO-B be measured. With citalopram as substrate, R-citalopram propionate was preferentially produced, whereas with demethyland didemethylcitalopram as substrates, mostly S-citalopram propionate formation was detected (Table 3) .
With human brain mitochondria, demethylcitalopram was found to be the best substrate, resulting in a 3.3 times higher citalopram propionate production in the frontal cortex than with R-citalopram from which the lowest production resulted. The lowest activity of citalopram propionate production in human brain was in the white matter, and slightly higher in the frontal cortex and cerebellum, the highest being in the putamen. In the putamen, activities were 1.3 times (substrate: R-citalopram), 2.1 times (citalopram), 2.2 times (demethylcitalopram), 2.3 times (didemethylcitalopram) and 2.7 times (S-citalopram) higher than in frontal cortex (Table 1) . Table 2 shows the relative contributions of MAO-A and MAO-B expressed as a percentage of total MAO activity. In human brain, MAO-B activity predominated. The only exception was the substrate R-citalopram, which was metabolised by about 45% by MAO-A and between 14% and 20% by MAO-B in the frontal cortex, the cerebellum and the putamen. MAO-A activity represented 35% in frontal cortex with citalopram as substrate and 2.2% in putamen with didemethylcitalopram as substrate. MAO-B activity was highest with demethyl-and didemethylcitalopram as substrates (over 75%) and between 39% and 67% with citalopram and S-citalopram as substrates. Differences in the relative contributions of MAO-A and MAO-B between the various human brain regions were small.
Few differences were seen between human brain regions with respect to the stereoselectivity of MAO towards the racemic substrates citalopram and Ndemethylated metabolites (Table 3) . MAO-B activity led in all tissues and with all substrates to the preferential production of S-citalopram propionate. In contrast, with citalopram as substrate, MAO-A catalised preferentially the formation of R-citalopram propionate whereas with demethyl-and didemethylcitalopram as substrates, the S-to R-citalopram propionate ratio varied from 1.08 to 1. protein). V max was very similar for MAO-A and B, but K m was lower for MAO-B.
Discussion
As shown earlier in human liver 20 and in human blood, 21 our study confirms that also in human and rat brains, citalopram and its N-demethylated metabolites are stereoselectively metabolised by MAO. Whereas Ndemethylation of citalopram by P450 represents a major pathway in the liver, 18, 19 N-demethylation of citalopram by P450s could not be measured in our samples of rat brain-tissue.
In brain, activity of drug-metabolising P450s is low, 1-5% relative to the liver. 36 As sensitive analytical methods have to be used for the detection of weakly produced metabolites, the contamination of substrates with metabolites becomes a major problem. We found citalopram to contain 0.2% of demethylcitalopram. Under these circumstances, we were not able to detect any citalopram demethylase activity mediated by P450s in rat brain microsomes. As demethylcitalopram is a better substrate for MAO than citalopram, we blocked MAO-A and B completely with specific MAO inhibitors but even so, we failed to observe any production of demethylcitalopram in rat brain (results not shown). CYP2D6 and CYP3A4-like activities in human brain microsomes were found to be less than that observed in rat brain microsomes by assessing amitriptyline N-demethylase and dextromethorphan O-demethylase activities. 30 With CYP2C19, they are the main enzymes implicated in citalopram N-demethylation in human liver. Therefore, we did not investigate citalopram metabolism by P450 in human brain microsomes. Our results in rat brain support the hypothesis that P450 is not the major enzyme system implicated in the metabolism of citalopram in the brain.
MAO activities were measured in whole rat brains and in human brain autopsy material. The human tissue was taken from brains of 75-98 year old subjects. MAO-A activity of the frontal cortex remains constant during adult life, whereas MAO-B activity increases from 60 years onwards in a non-linear manner. 37 It has also been shown, that MAO-B activity may be decreased in the brain of smokers in comparison to non-smokers. 38 We could not find information about the smoking status of our subjects. The relative contribution of MAO-B in human brain as found in our studies might be higher than what might be expected in younger adults but perhaps lower than in non-smokers. There is also evidence that drugs such as dexamethasone show a robust induction of MAO-A activity and to a lesser extent also MAO-B activity. 39 Apparently, our subjects were not medicated with compounds known to be MAO inducers.
Production of H 2 O 2 reflects total activity of MAO whereas the detection of citalopram propionate may not quantitatively reflect the activity of the MAOs. Indeed, they deaminate citalopram to yield the hypothetical metabolic intermediate citalopram propionic aldehyde. This compound could undergo transformations which would result not only in the production of citalopram propionate, but also other hypothetical metabolites such as citalopram propionic alcohol. 20 Unfortunately, these potential metabolites were not available for experimental purposes. However, unknown metabolites should only be of minor importance. 22 Levels of H 2 O 2 -production in rat brain mitochondria were 1.7 times, 2.3 times, 3.6 times and 4.5 times higher with S-citalopram, citalopram, R-citalopram and demethylcitalopram as substrates respectively, than the measured production of citalopram propionate (Table 1 ). These differences may also be partly explained by the different incubation methods used. Where H 2 O 2 -production was measured, this was carried out at pH 8, which is the optimal value for this assay. In the incubations, where the production of citalopram propionate was measured, the pH was 7.4. The relative activities of MAO-A and MAO-B (Table 2) are, however, similar between the two methods.
In rat brain, MAO activities were 3.7 times (substrate: R-citalopram), 4.4 times (citalopram), 7.3 times (demethylcitalopram), 7.6 times (S-citalopram) and 9.1 times (didemethylcitalopram) lower than in human frontal cortex (Table 1) . Whereas in rat brain MAO-A activity was found to be higher than MAO-B activity, in human brain MAO-B activity predominated. These data are in line with earlier observations. Thus, in rat brain, MAO-A represents 55% of total MAO-activity, whereas in human brain it amounts only to 20%. 40 In two other studies, MAO-A and MAO-B content and distribution in the human and rat brain were examined by quantitative enzyme autoradiography. 41, 42 According to these authors, in rat brain cortex, MAO-A and MAO-B levels were similar and MAO-A levels in human and in rat brain were also comparable. In human brain, the ratio of MAO-B to MAO-A content was 5.7:1 in temporal cortex, 7:1 in putamen, 17:1 in the white matter of the temporal cortex and about 5:1 in the cerebellum. MAO-B content in the putamen was therefore 1.1 times higher than in temporal cortex and 2.2 times higher than in white matter of temporal cortex, which contained about the same amount as cerebellar cortex. In our study using human brain, didemethycitalopram seems to be almost exlusively metabolised by MAO-B. In the putamen, we found a 2.3 times higher didemethylcitalopram deaminating activity than in frontal cortex, 1.8 times higher than in the cerebellum and 4.3 times higher than in the white matter of the frontal cortex.
Demethyl-and didemethylcitalopram, the secondary and primary amines, were found to be better substrates for MAO than citalopram, the tertiary amine, and its Sand R-enantiomers (Table 1) . Similar observation was made using human liver microsomes. 20 Also, the stereoselective production of R-and S-citalopram propionate was confirmed. In human brain, S-citalopram was a better substrate than R-citalopram, whereas in rat brain the two enantiomers were metabolised at about the same rate. According to Table 3 , a clear stereoselective metabolism of citalopram and demethyland didemethylcitalopram is evident: MAO-A, compared to MAO-B, preferentially catalysed the formation of R-citalopram propionate from these racemic substrates both in rat and in human brain (with S/R-citalopram propionate ratios varying between 0.72 and 1.4). In contrast, S/R-citalopram propionate ratios varied from 2.1 (cerebellum, with citalopram as substrate) to 21 (putamen, didemethylcitalopram as substrate), as a consequence of MAO-B activity. The stereoselectivity of MAO is complex and not yet fully understood, 43 but interestingly, in human blood, where only MAO-B occurs (in the platelets), S-citalopram is more readily deaminated than R-citalopram. 21 Despite the fact that citalopram propionate production might not reflect quantitatively MAO activity, the apparent K m and V max values of S-citalopram deamination were measured in human brain mitochondria (Figure 1 At 0.25 mM substrate in the incubation mixture, the production of R-citalopram propionate from R-citalopram was at the limit of quantification, especially after blocking MAO-A and the data did not allow a meaningful calculation of the K m and V max values.
The fact that citalopram is metabolised by MAO does not, in itself, imply that it is a clinically relevant MAOinhibitor. According to other observations (C Gnerre et al, revised manuscript submitted), kynuramine deamination by MAO-A is decreased by 32-40% in the presence of 1 mM citalopram, R-citalopram, S-citalopram or demethyl-and didemethylcitalopram in rat brain mitochondria measured according to Thull and Testa. 32 Under the same conditions, MAO-B activity was decreased by 70 and 77%. Thus, citalopram, its enantiomers and demethylated metabolites are competing with kynuramine for the catalytic site of MAO and they have a greater affinity for MAO-B than for MAO-A. However, citalopram was found to have a lower affinity for MAO-A and B compared to fluoxetine and no inhibitory action on the binding of clorgyline and methylpropargylamine to either MAO-A or MAO-B. 24, 44 The competing for binding sites depends however on both, the affinity as well as the respective concentrations of the compounds. The extent to which citalopram in a therapeutic setting may interfere with the metabolism of monoamine substrates catalysed by MAO in the brain remains to be investigated. To our knowledge, local citalopram concentrations in the brain of patients routinely treated with citalopram are not known.
Citalopram is generally a safe antidepressant, 45, 46 even in intoxicating doses. 47 Below 600 mg, citalopram caused only mild symptoms. At higher doses (600-3000 mg), which correspond to a 15-75 fold daily dose, the risk for ECG abnormalities and convulsions increased, but all patients recovered. Other intoxications with citalopram were reportedly fatal 48 or nonfatal. 49 The description of three fatal cases of a citalopram-moclobemide intoxication however point to the increased risk of a serotonin syndrome with a lethal outcome using such a combination, even if plasma concentrations of citalopram were not exceedingly high. 16 Pharmacodynamically, citalopram may be considered an SSRI having additional weak MAOinhibiting properties. Since it is also metabolised by this enzyme, one might expect co-administration with an MAO-inhibitor to prolong the action of citalopram by inhibiting its metabolism in brain and to increase its local concentration. The present in vitro findings support this idea but can neither confirm nor refute it. Further studies are needed to evaluate the risks of a prolonged inhibition of the metabolism of citalopram even after discontinuation of the MAO inhibitory treatment.
Molecular Psychiatry
To our knowledge, this is the first time that evidence is provided for the in vitro biotransformation of an antidepressant by MAO in rat and human brain mitochondria. Our results support the hypothesis that in brain, deamination of citalopram by MAO constitutes the main metabolic pathway, and that metabolism by P450, in contrast to the liver, has to be considered of minor importance.
Finally, our results raise general questions about the regulation of drug metabolism by exogenous and genetic factors. It has been shown that there is a significant association between allele distribution of MAO-A and pathological gambling, 50 and several reports deal with the relationship between bipolar disorder, alcoholism, smoking or impulsive behavior and MAO polymorphisms. 51, 52 The metabolism of drugs like citalopram could depend, at least partially, on what is generally considered as 'psychological' factors, related in this case to MAO polymorphisms. In this respect, it is interesting that antidepressants of the SSRI type have been proposed for the treatment of above-mentioned psychiatric conditions. 53 
